· News

POELLATH advises Inflexion on its investment in Proteros biostructures GmbH

The leading mid-market private equity firm Inflexion Private Equity Partners LLP (“Inflexion”) has acquired a minority stake in Proteros biostructures GmbH (“Proteros”) by Inflexion’s dedicated minority fund, Partnership Capital II. Founder and CEO Dr. Torsten Neuefeind retains the majority shareholding in Proteros and will continue to lead the company. The transaction is subject to customary regulatory approvals and is expected to close in Q1 2023.

Munich-based Proteros is a specialist in structural biology and has created a cutting-edge platform recognised globally by both large pharma and biotechs as capable of unlocking the most technically challenging drug targets. Proteros supports many of the world’s top 20 largest pharmaceutical companies and over 200 pharma and biotech partners in the US, Europe and Japan to reach the right results and accelerate their overall research timelines, helping them to lead optimisation and clinical programmes.

Together with Travers Smith LLP (led by Partner Tom Hartwright) POELLATH, as German counsel for Inflexion, provided comprehensive legal advice within the context of the transaction with the following team:

Press contact